Aligos Therapeutics Stock Filter Stocks by Fundamentals
| ALGS Stock | USD 25.51 2.52 10.96% |
Aligos Therapeutics fundamentals help investors to digest information that contributes to Aligos Therapeutics' financial success or failures. It also enables traders to predict the movement of Aligos Stock. The fundamental analysis module provides a way to measure Aligos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aligos Therapeutics stock.
Aligos | Cash and Equivalents |
Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| All Next | Launch Module |
Aligos Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aligos Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aligos Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aligos Fundamentals
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.67 | ||||
| Operating Margin | (15.86) % | ||||
| Current Valuation | 25.74 M | ||||
| Shares Outstanding | 3.46 M | ||||
| Shares Owned By Insiders | 17.79 % | ||||
| Shares Owned By Institutions | 48.80 % | ||||
| Number Of Shares Shorted | 291.5 K | ||||
| Price To Book | 1.83 X | ||||
| Price To Sales | 14.74 X | ||||
| Revenue | 15.53 M | ||||
| Gross Profit | (71.17 M) | ||||
| EBITDA | (85.06 M) | ||||
| Net Income | (87.68 M) | ||||
| Cash And Equivalents | 159.34 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 11.14 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 5.30 X | ||||
| Book Value Per Share | 15.07 X | ||||
| Cash Flow From Operations | (79 M) | ||||
| Short Ratio | 0.73 X | ||||
| Earnings Per Share | (7.25) X | ||||
| Target Price | 103.33 | ||||
| Number Of Employees | 68 | ||||
| Beta | 2.12 | ||||
| Market Capitalization | 88.37 M | ||||
| Total Asset | 151.53 M | ||||
| Retained Earnings | (486.8 M) | ||||
| Working Capital | 117.18 M | ||||
| Net Asset | 151.53 M |
About Aligos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aligos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aligos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aligos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.